drugset / Trial / NCT00515073

Papillary Serous Carcinoma of the Endometrium

NCT00515073

Phase 2 Completed 30 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

Primary Objectives: * To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival. * To evaluate the toxicity of Paclitaxel and pelvic radiation. * To collect and evaluate patients' quality of life/symptom assessment data.

Timeline

Start
2001-04
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 50 mg/m2 Intravenous
Subject Paclitaxel Small molecule 135 mg/m2 Intravenous
Background Cimetidine Small molecule 300 mg Intravenous
Background Dexamethasone Small molecule 20 mg Intravenous
Background Diphenhydramine Unknown 50 mg Intravenous

Indications